Routes of
administration Oral Legal status Investigational PubChem CID 10117987 Molar mass 503.555 g/mol | ATC code none CAS Number 377727-87-2 IUPHAR/BPS 5614 | |
 | ||
How to pronounce preladenant
Preladenant (SCH 420814) was a drug that was developed by Schering-Plough which acted as a potent and selective antagonist at the adenosine A2A receptor. It was being researched as a potential treatment for Parkinson's disease. Positive results were reported in Phase II clinical trials in humans, but it did not prove itself to be more effective than a placebo during Phase III trials, and so was discontinued in May 2013.
References
Preladenant Wikipedia(Text) CC BY-SA